This post was originally published on this site A literature review of research performed in specific populations from countries worldwide estimated a heritability of 60 to 70 percent for familial sarcoidosis, a study has found. The study titled “Clinical epidemiology of familial sarcoidosis: A systematic literature review” was published in the journal Respiratory Medicine. While…
This post was originally published on this site Scores of events are afoot worldwide to mark Feb. 28, Rare Disease Day 2019. The activities aim to raise awareness about rare diseases and the millions of people — estimates run as high as 350 million — they are thought to impact. Across countries, patients, caregivers and advocates will paint faces,…
This post was originally published on this site Monitoring Hodgkin’s lymphoma patients with positron-emission tomography (PET) scans during chemotherapy can help identify those who respond early to a more intense chemotherapy regimen and switch them to a softer, less toxic regimen, helping to avoid adverse side effects while maintaining the same chance of successful treatment,…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted priority review to Revlimid (lenalidomide) in combination with Rituxan (rituximab) for patients with previously treated follicular and marginal zone lymphoma. A decision on whether to approve the treatment combination is expected by June 27. Celgene’s supplemental New Drug Application…
This post was originally published on this site A Phase 1 trial testing the combination of ADCT-402 (loncastuximab tesirine) with Imbruvica (ibrutinib) for advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) has dosed the first patient. Patient enrollment, for a planned total of 60 participants, is ongoing in the U.S. and Belgium. More information…
This post was originally published on this site The U.S. Food and Drug Administration has granted priority review to Roche‘s polatuzumab vedotin in combination with Rituxan (rituximab) and the chemotherapy bendamustine for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The FDA is expected to make a decision on whether to approve…
This post was originally published on this site Health Canada has approved Yescarta (axicabtagene ciloleucel) as a treatment for adults with diffuse large B-cell lymphoma (DLBCL) who have already received two or more lines of systemic therapy. Specifically, the agency’s Notice of Compliance covers relapsed or refractory patients with unspecified DLBCL, primary mediastinal (thymic) large…
This post was originally published on this site The European Commission (EC) granted marketing authorization to Roche for Tecentriq (atezolizumab) as a monotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior treatment with chemotherapy, the company announced in a press release. Tecentriq can be administered regardless of PD-L1 status, and patients that have EGFR-activating mutations or ALK-positive tumor…
This post was originally published on this site Elderly people with early-stage lung cancer might also benefit from stereotactic body radiation therapy (SBRT), finds a study of more than 1,000 patients. The study, “Stereotactic Body Radiation Therapy in Octo- and Nonagenarians for the Treatment of Early-Stage Lung Cancer,” appeared in the International Journal of Radiation Oncology • Biology…
This post was originally published on this site Pharmatest Services, in collaboration with Taconic Biosciences, has developed a new experimental mouse model with a human immune system specifically engineered to study bone metastasis — a frequent consequence of many cancers, including breast, prostate, and lung cancer. “Despite its high frequency in breast, prostate, and lung cancer…
